Skip to main content
SpringerLink
Log in

Nitrated Proteins in the Progression of Alzheimer’s Disease: A Proteomics Comparison of Mild Cognitive Impairment and Alzheimer’s Disease Brain

  • Chapter
  • First Online:
Oxidative Neural Injury

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

Abstract

Oxidative stress and nitrosative stress have been reported to play important roles in the pathogenesis of a number of diseases including neurodegenerative diseases, cancer, ischemia, etc. Reactive nitrogen species are highly reactive and unstable. One of the best ways to quantify the amount of nitrosative stress is to measure the levels of 3-nitrotyrosine level. In addition, by using proteomics selective targets of protein nitration can be identified. In this chapter we discuss the roles of proteomics-identified nitrated brain proteins to the pathology of both mild cognitive impairment and Alzheimer’s disease. The identity of these nitrated proteins improves understanding of the role of nitrosative stress in the pathogenesis and progression of disease from MCI to AD. Such studies could also help in early detection and may provide therapeutic targets for early treatment that may slow disease progression.

This paper is dedicated to the life of Dr. Earl R. Stadtman (1919–2008), a good friend and accomplished scientist and mentor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bruijn LI, Beal MF, Becher MW, Schulz JB, Wong PC, Price DL, Cleveland DW. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7606–7611.

    Google Scholar 

  2. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal. 2006 Nov–Dec;8(11–12):1975–1986.

    Google Scholar 

  3. Kunz A, Park L, Abe T, Gallo EF, Anrather J, Zhou P, Iadecola C. Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci. 2007 Jul 4;27(27):7083–7093.

    Google Scholar 

  4. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis. 2007 May;11(2):207–218.

    Google Scholar 

  5. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006 Jun;97(6):1676–1689.

    Google Scholar 

  6. Bergendi L, Benes L, Durackova Z, Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sci. 1999;65(18–19):1865–1874.

    Article  PubMed  CAS  Google Scholar 

  7. Toader V, Xu X, Nicolescu A, Yu L, Bolton JL, Thatcher GR. Nitrosation, nitration, and autoxidation of the selective estrogen receptor modulator raloxifene by nitric oxide, peroxynitrite, and reactive nitrogen/oxygen species. Chem Res Toxicol. 2003 Oct;16(10):1264–1276.

    Google Scholar 

  8. Lafon-Cazal M, Culcasi M, Gaven F, Pietri S, Bockaert J. Nitric oxide, superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacology. 1993 Nov;32(11):1259–1266.

    Google Scholar 

  9. Kawano T, Kunz A, Abe T, Girouard H, Anrather J, Zhou P, Iadecola C. iNOS-derived NO and nox2-derived superoxide confer tolerance to excitotoxic brain injury through peroxynitrite. J Cereb Blood Flow Metab. 2007 Aug;27(8):1453–1462.

    Google Scholar 

  10. Souza JM, Daikhin E, Yudkoff M, Raman CS, Ischiropoulos H. Factors determining the selectivity of protein tyrosine nitration. Arch Biochem Biophys. 1999 Nov 15;371(2):169–178.

    Google Scholar 

  11. Butterfield DA, Stadtman ER. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol; 1997. 2:161–191.

    Article  CAS  Google Scholar 

  12. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem. 2003 Jun;85(6):1394–1401.

    Google Scholar 

  13. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem. 1999 Jan;72(1):310–317.

    Google Scholar 

  14. Sampson JB, Rosen H, Beckman JS. Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Methods Enzymol. 1996;269:210–218.

    Article  PubMed  CAS  Google Scholar 

  15. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med. 2007 Jul–Aug;11(4):839–851.

    Google Scholar 

  16. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J Neurosci. 2002 May 15;22(10):3987–3993.

    Google Scholar 

  17. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys. 1992 Nov 1;298(2):431–437.

    Google Scholar 

  18. Gow AJ, Duran D, Malcolm S, Ischiropoulos H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett. 1996 Apr 29;385(1–2):63–66.

    Google Scholar 

  19. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis. 2006 Apr;22(1):76–87.

    Google Scholar 

  20. Aulak KS, Koeck T, Crabb JW, Stuehr DJ. Dynamics of protein nitration in cells and mitochondria. Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H30–H38.

    Google Scholar 

  21. Koeck T, Fu X, Hazen SL, Crabb JW, Stuehr DJ, Aulak KS. Rapid and selective oxygen-regulated protein tyrosine denitration and nitration in mitochondria. J Biol Chem. 2004 Jun 25;279(26):27257–27262.

    Google Scholar 

  22. Butterfield DA. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol. 1997 May;10(5):495–506.

    Google Scholar 

  23. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–298.

    Article  PubMed  CAS  Google Scholar 

  24. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002 Aug 30;277(35):32046–32053.

    Google Scholar 

  25. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging. 2003 May–Jun;24(3):415–420.

    Google Scholar 

  26. Fawzi NL, Kohlstedt KL, Okabe Y, Head-Gordon T. Protofibril assemblies of the Arctic, Dutch and Flemish mutants of the Alzheimer's A{beta}1–40 Peptide. Biophys J. 2007;44(6):2007–2016.

    Google Scholar 

  27. Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J. 2001 May 1;355(Pt 3):869–877.

    Google Scholar 

  28. Shen J, Kelleher RJ, 3rd. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):403–409.

    Google Scholar 

  29. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev. 2002 Sep;54(3):469–525.

    Google Scholar 

  30. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):678–680.

    Google Scholar 

  31. de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging. 2000 Mar–Apr;21(2):309–319.

    Google Scholar 

  32. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353–356.

    Google Scholar 

  33. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001 Dec;7(12):548–554.

    Google Scholar 

  34. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003 Oct 31;278(44):42959–42965.

    Google Scholar 

  35. Lauderback CM, Hackett JM, Keller JN, Varadarajan S, Szweda L, Kindy M, Markesbery WR, Butterfield DA. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1–40): implications for Alzheimer's disease. Biochemistry. 2001 Feb 27;40(8):2548–2554.

    Google Scholar 

  36. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23(1):134–147.

    Article  PubMed  CAS  Google Scholar 

  37. Butterfield DA, Koppal T, Subramaniam R, Yatin S. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci. 1999;10(2):141–149.

    Article  PubMed  CAS  Google Scholar 

  38. Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol. 2001 Mar;58(3):392–396.

    Google Scholar 

  39. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol. 1997 May;10(5):485–494.

    Google Scholar 

  40. Butterfield DA. Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res. 2002 Dec;36(12):1307–1313.

    Google Scholar 

  41. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002 Jun 1;32(11):1050–1060.

    Google Scholar 

  42. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 2002 Sep;82(6):1524–1532.

    Google Scholar 

  43. Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YL, Osaka H, Wada K, Butterfield DA. Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem. 2004 Mar;88(6):1540–1546.

    Google Scholar 

  44. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997 Apr 15;17(8):2653–2657.

    Google Scholar 

  45. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging. 2006 Nov;27(11):1564–1576.

    Google Scholar 

  46. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 1998 Oct 15;18(20):8126–8132.

    Google Scholar 

  47. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol. 2003 Sep;163(3):1021–1031.

    Google Scholar 

  48. Zhang YJ, Xu YF, Liu YH, Yin J, Li HL, Wang Q, Wang JZ. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. Faseb J. 2006 Jul;20(9):1431–1442.

    Google Scholar 

  49. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005 Jul;62(7):1160–1163; discussion 1167.

    Google Scholar 

  50. Nacmias B, Piccini C, Bagnoli S, Tedde A, Cellini E, Bracco L, Sorbi S. Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer's disease. Neurosci Lett. 2004 Sep 9;367(3):379–383.

    Google Scholar 

  51. Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Winblad B. Mild cognitive impairment – an early stage of Alzheimer's disease? J Neural Transm Suppl. 1998;54:21–29.

    PubMed  CAS  Google Scholar 

  52. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007 May 7;1148:243–248.

    Google Scholar 

  53. Sultana R, Piroddi M, Galli F, Butterfield DA. Protein levels and activity of some antioxidant enzymes in amnestic mild cognitive impairment and control hippocampus. Neurochem Res. 2008 Dec;33(12):2540–2546.

    Google Scholar 

  54. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003 Nov;24(7):915–919.

    Google Scholar 

  55. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006 Feb;27(2):262–269.

    Google Scholar 

  56. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem. 2006 Feb;96(3):825–832.

    Google Scholar 

  57. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007;35(22):7497–7504.

    Article  PubMed  CAS  Google Scholar 

  58. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis. 2007;4(6):403–405.

    Article  PubMed  CAS  Google Scholar 

  59. Cenini G, Sultana R, Memo M, Butterfield DA. Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J Cell Mol Med. 2007 Jun;12(3):987–994.

    Google Scholar 

  60. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2006 Aug;27(8):1094–1099.

    Google Scholar 

  61. Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol. 2007 Jul;64(7):954–956.

    Google Scholar 

  62. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006 Apr 24;397(3):170–173.

    Google Scholar 

  63. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005 Apr 12;64(7):1152–1156.

    Google Scholar 

  64. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis. 2007 Aug;12(1):61–72.

    Google Scholar 

  65. Dalle-Donne I, Scaloni A, Butterfield DA. Redox proteomics: from protein modifications to cellular dysfunction and diseases. John Wiley and Sons, Hoboken, NJ. 2006.

    Book  Google Scholar 

  66. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol. 2006 Sep 1;545(1):39–50.

    Google Scholar 

  67. Sultana R, Perluigi M, Butterfield DA. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1–42). J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Mar 20;833(1):3–11.

    Google Scholar 

  68. Aksenova M, Butterfield DA, Zhang SX, Underwood M, Geddes JW. Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J Neurotrauma. 2002 Apr;19(4):491–502.

    Google Scholar 

  69. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. 2006 May;22(2):223–232.

    Google Scholar 

  70. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr. 1984 Jul;3(2):161–165.

    Google Scholar 

  71. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry. 2003 Jun;36 Suppl 1:S62–S67.

    Google Scholar 

  72. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci. 2004 Mar 10;24(10):2401–2411.

    Google Scholar 

  73. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene. 1996 Nov 21;180(1–2):157–163.

    Google Scholar 

  74. Kato Y, Hamajima N, Inagaki H, Okamura N, Koji T, Sasaki M, Nonaka M. Post-meiotic expression of the mouse dihydropyrimidinase-related protein 3 (DRP-3) gene during spermiogenesis. Mol Reprod Dev. 1998 Sep;51(1):105–111.

    Google Scholar 

  75. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging. 1987 Nov–Dec;8(6):521–545.

    Google Scholar 

  76. Adams JC. Formation of stable microspikes containing actin and the 55 kDa actin bundling protein, fascin, is a consequence of cell adhesion to thrombospondin-1: implications for the anti-adhesive activities of thrombospondin-1. J Cell Sci. 1995;108:1977–1990.

    PubMed  CAS  Google Scholar 

  77. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004;16:590–596.

    Article  PubMed  CAS  Google Scholar 

  78. Pinkus GS, Lones MA, Matsumura F, Yamashiro S, Said JW, Pinkus JL. Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol. 2002 Sep;118(3):335–343.

    Google Scholar 

  79. Graziewicz MA, Day BJ, Copeland WC. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res. 2002 Jul 1;30(13):2817–2824.

    Google Scholar 

  80. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D, Patterson D. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet. 1993 Jul;53(1):220–233.

    Google Scholar 

  81. Tchaikovskaya T, Fraifeld V, Urphanishvili T, Andorfer JH, Davies P, Listowsky I. Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer's disease. Mech Ageing Dev. 2005 Feb;126(2):309–315.

    Google Scholar 

  82. Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, Butterfield DA. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res. 2007 Feb 15;85(3):497–503.

    Google Scholar 

  83. Renes J, de Vries EE, Hooiveld GJ, Krikken I, Jansen PL, Muller M. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J. 2000 Sep 1;350 Pt 2:555–561.

    Google Scholar 

  84. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res. 2004 Dec;29(12):2215–2220.

    Google Scholar 

  85. Peshenko IV, Shichi H. Oxidation of active center cysteine of bovine 1-Cys peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxynitrite. Free Radic Biol Med. 2001 Aug 1;31(3):292–303.

    Google Scholar 

  86. Ralat LA, Manevich Y, Fisher AB, Colman RF. Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry. 2006 Jan 17;45(2):360–372.

    Google Scholar 

  87. Lu KP. Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog Cell Cycle Res. 2000;4:83–96.

    Article  PubMed  CAS  Google Scholar 

  88. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature. 1999 Jun 24;399(6738):784–788.

    Google Scholar 

  89. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging. 2006 Jul;27(7):918–925.

    Google Scholar 

  90. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001 Aug;26(8):504–510.

    Google Scholar 

  91. Hoshino T, Nakaya T, Araki W, Suzuki K, Suzuki T, Mizushima T. Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. Biochem J. 2007 Mar 15;402(3):581–589.

    Google Scholar 

  92. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci. 2004 Apr 15;117(Pt 10):1875–1884.

    Google Scholar 

  93. Takahashi Y. The 14-3-3 proteins: gene, gene expression and function. Neurochem Res. 2003;28:1265–1273.

    Article  PubMed  CAS  Google Scholar 

  94. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer RJ. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett. 1996 May 3;209(1):57–60.

    Google Scholar 

  95. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology. 2001 Jun 12;56(11):1528–1533.

    Google Scholar 

  96. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1–42) into rat brain: implications for Alzheimer's disease. Neuroscience. 2005;132(2):313–324.

    Article  PubMed  CAS  Google Scholar 

  97. Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362–8366.

    Google Scholar 

  98. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, Lin R, Paudel HK. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem. 2003 Apr 11;278(15):12722–12728.

    Google Scholar 

  99. Hashiguchi M, Sobue K, Paudel HK. 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem. 2000 Aug 18;275(33):25247–25254.

    Google Scholar 

  100. Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab. 1989 Feb;9(1):2–19.

    Google Scholar 

  101. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol. 2004;541:135–152.

    Article  PubMed  CAS  Google Scholar 

  102. Rapoport SI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1999;249:46–55.

    Article  PubMed  Google Scholar 

  103. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci. 1999;893:154–175.

    Article  PubMed  CAS  Google Scholar 

  104. Vanhanen M, Soininen H. Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol. 1998 Dec;11(6):673–677.

    Google Scholar 

  105. Kish SJ, Lopes-Cendes I, Guttman M, Furukawa Y, Pandolfo M, Rouleau GA, Ross BM, Nance M, Schut L, Ang L, DiStefano L. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch Neurol. 1998 Oct;55(10):1299–1304.

    Google Scholar 

  106. Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem. 2001 Jan;76(2):442–449.

    Google Scholar 

  107. Hara MR, Cascio MB, Sawa A. GAPDH as a sensor of NO stress. Biochim Biophys Acta. 2006 May;1762(5):502–509.

    Google Scholar 

  108. Blass JP, Gibson GE, Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis. 2002 Jun;4(3):225–232.

    Google Scholar 

  109. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005 May;57(5):695–703.

    Google Scholar 

  110. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging. 2002 May–Jun;23(3):371–376.

    Google Scholar 

  111. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001 May 1;21(9):3017–3023.

    Google Scholar 

  112. Schagger H, Ohm TG. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur J Biochem. 1995 Feb 1;227(3):916–921.

    Google Scholar 

  113. Sergeant N, Wattez A, Galvan-valencia M, Ghestem A, David JP, Lemoine J, Sautiere PE, Dachary J, Mazat JP, Michalski JC, Velours J, Mena-Lopez R, Delacourte A. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience. 2003;117(2):293–303.

    Article  PubMed  CAS  Google Scholar 

  114. Weeber EJ, Levy M, Sampson MJ, Anflous K, Armstrong DL, Brown SE, Sweatt JD, Craigen WJ. The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem. 2002 May 24;277(21):18891–18897.

    Google Scholar 

  115. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ. 2005 Jul;12(7):751–760.

    Google Scholar 

  116. Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis. 2001 Jan;22(1):172–179.

    Google Scholar 

  117. Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol. 2001 Dec 10;155(6):1003–1015.

    Google Scholar 

  118. Shimizu H, Banno Y, Sumi N, Naganawa T, Kitajima Y, Nozawa Y. Activation of p38 mitogen-activated protein kinase and caspases in UVB-induced apoptosis of human keratinocyte HaCaT cells. J Invest Dermatol. 1999 May;112(5):769–774.

    Google Scholar 

  119. Du C, Fang, M., Li, Y., Li, L., Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activiation by eliminating IAP inhibition. Cell 2000;102:33–42.

    Article  PubMed  CAS  Google Scholar 

  120. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341:233–249.

    Article  PubMed  CAS  Google Scholar 

  121. Bader Lange ML, Cenini G, Piroddi M, Mohmmad Abdul H, Sultana R, Galli F, Memo M, Butterfield DA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis. 2008 Mar;29(3):456–464.

    Google Scholar 

  122. Abdul H, Butterfield D. Protection against amyloid beta-peptide(1–42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochem Biophys Acta. 2005;1741:140–148.

    Google Scholar 

  123. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. 2004 Apr 9;1004(1–2):193–197.

    Google Scholar 

  124. Ojika K. Hippocampal cholinergic neurostimulating peptide. Seikagaku. 1998 Sep;70(9):1175–1180.

    Google Scholar 

  125. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403.

    Google Scholar 

  126. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983 Mar 11;219(4589):1184–1190.

    Google Scholar 

  127. Wevers A, Witter B, Moser N, Burghaus L, Banerjee C, Steinlein OK, Schutz U, de Vos RA, Steur EN, Lindstrom J, Schroder H. Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? Acta Neurol Scand Suppl. 2000;176:42–48.

    Article  PubMed  CAS  Google Scholar 

  128. Maki M, Matsukawa N, Yuasa H, Otsuka Y, Yamamoto T, Akatsu H, Okamoto T, Ueda R, Ojika K. Decreased expression of hippocampal cholinergic neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer disease. J Neuropathol Exp Neurol. 2002 Feb;61(2):176–185.

    Google Scholar 

  129. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med. 1999 Dec;27(11–12):1151–1163.

    Google Scholar 

  130. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem. 1995;64:375–401.

    Article  PubMed  CAS  Google Scholar 

  131. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl. 1999;57:161–177.

    PubMed  CAS  Google Scholar 

  132. Kaech S, Brinkhaus H, Matus A. Volatile anesthetics block actin-based motility in dendritic spines. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10433–10437.

    Google Scholar 

  133. di Campli A, Valderrama F, Babia T, De Matteis MA, Luini A, Egea G. Morphological changes in the Golgi complex correlate with actin cytoskeleton rearrangements. Cell Motil Cytoskeleton. 1999;43(4):334–348.

    Article  PubMed  Google Scholar 

  134. Valderrama F, Luna A, Babia T, Martinez-Menarguez JA, Ballesta J, Barth H, Chaponnier C, Renau-Piqueras J, Egea G. The golgi-associated COPI-coated buds and vesicles contain beta/gamma -actin. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1560–1565.

    Google Scholar 

  135. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 2001;103(2):373–383.

    Article  PubMed  CAS  Google Scholar 

  136. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000;15(3):93–101.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by NIH grants to D.A.B. [AG-10836 and AG-05119].

Author information

Authors and Affiliations

  1. Department of Chemistry, University of Kentucky, Lexington, KY 40506, USA

    Rukhsana Sultana, Renã A. Sowell & D. Allan Butterfield

  2. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA

    D. Allan Butterfield

Authors
  1. Rukhsana Sultana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renã A. Sowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Allan Butterfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Allan Butterfield .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Sultana, R., Sowell, R.A., Butterfield, D.A. (2009). Nitrated Proteins in the Progression of Alzheimer’s Disease: A Proteomics Comparison of Mild Cognitive Impairment and Alzheimer’s Disease Brain. In: Veasey, S. (eds) Oxidative Neural Injury. Contemporary Clinical Neuroscience. Humana Press. https://doi.org/10.1007/978-1-60327-342-8_9

    Download citation

    Publish with us

    Policies and ethics

    Search

    Navigation